Formulation Design of Dry Powders for Inhalation

Drugs for inhalation are no longer exclusively highly crystalline small molecules. They may also be amorphous small molecules, peptides, antibodies, and myriad types of engineered proteins. The evolution of respiratory therapeutics has created a need for flexible formulation technologies to engineer...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of pharmaceutical sciences 2015-10, Vol.104 (10), p.3259-3288
Hauptverfasser: Weers, Jeffry G., Miller, Danforth P.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 3288
container_issue 10
container_start_page 3259
container_title Journal of pharmaceutical sciences
container_volume 104
creator Weers, Jeffry G.
Miller, Danforth P.
description Drugs for inhalation are no longer exclusively highly crystalline small molecules. They may also be amorphous small molecules, peptides, antibodies, and myriad types of engineered proteins. The evolution of respiratory therapeutics has created a need for flexible formulation technologies to engineer respirable particles. These technologies have enabled medicinal chemists to focus on molecular design without concern regarding compatibility of physicochemical properties with traditional, blend-based technologies. Therapeutics with diverse physicochemical properties can now be formulated as stable and respirable dry powders. Particle engineering technologies have also driven the deployment of new excipients, giving formulators greater control over particle and powder properties. This plays a key role in enabling efficient delivery of drugs to the lungs. Engineered powder and device combinations enable aerosols that largely bypass the mouth and throat, minimizing the inherent variability among patients that arises from differences in oropharyngeal and airway anatomies and in breathing profiles. This review explores how advances among molecules, particles, and powders have transformed inhaled drug product development. Ultimately, this scientific progress will benefit patients, enabling new classes of therapeutics to be formulated as dry powder aerosols with improved efficacy, reduced variability and side effects, and improved patient adherence. © 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3259–3288, 2015
doi_str_mv 10.1002/jps.24574
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1710985272</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022354916301137</els_id><sourcerecordid>1710985272</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4674-497dfa3060eec326f97f31980e2caa1bedd22b52ff35c23614e4a31f9a84c5983</originalsourceid><addsrcrecordid>eNp10MtKAzEUBuAgitbLwheQATe6GJvrXJZSrRcEC-o6pJkTTZmZ1KSj9O1NndaF6CqBfPnP4UfomOALgjEdzubhgnKR8y00IILiNMMk30aD-EZTJni5h_ZDmGGMMyzELtqjGS1X1wHCY-ebrlYL69rkCoJ9bRNnkiu_TCbuswIfEuN8cte-qR4doh2j6gBH6_MAvYyvn0e36cPjzd3o8iHVPMt5ysu8MorFgQCa0cyUuWGkLDBQrRSZQlVROhXUGCY0ZRnhwBUjplQF16Is2AE663Pn3r13EBaysUFDXasWXBckyQkuC0FzGunpLzpznW_jdt8K8ziWRHXeK-1dCB6MnHvbKL-UBMtVjTLWKL9rjPZkndhNG6h-5Ka3CIY9-LQ1LP9PkveTp00k639ALO3DgpdBW2g1VNaDXsjK2T8W-QLEaotX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1710049801</pqid></control><display><type>article</type><title>Formulation Design of Dry Powders for Inhalation</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Alma/SFX Local Collection</source><creator>Weers, Jeffry G. ; Miller, Danforth P.</creator><creatorcontrib>Weers, Jeffry G. ; Miller, Danforth P.</creatorcontrib><description>Drugs for inhalation are no longer exclusively highly crystalline small molecules. They may also be amorphous small molecules, peptides, antibodies, and myriad types of engineered proteins. The evolution of respiratory therapeutics has created a need for flexible formulation technologies to engineer respirable particles. These technologies have enabled medicinal chemists to focus on molecular design without concern regarding compatibility of physicochemical properties with traditional, blend-based technologies. Therapeutics with diverse physicochemical properties can now be formulated as stable and respirable dry powders. Particle engineering technologies have also driven the deployment of new excipients, giving formulators greater control over particle and powder properties. This plays a key role in enabling efficient delivery of drugs to the lungs. Engineered powder and device combinations enable aerosols that largely bypass the mouth and throat, minimizing the inherent variability among patients that arises from differences in oropharyngeal and airway anatomies and in breathing profiles. This review explores how advances among molecules, particles, and powders have transformed inhaled drug product development. Ultimately, this scientific progress will benefit patients, enabling new classes of therapeutics to be formulated as dry powder aerosols with improved efficacy, reduced variability and side effects, and improved patient adherence. © 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3259–3288, 2015</description><identifier>ISSN: 0022-3549</identifier><identifier>EISSN: 1520-6017</identifier><identifier>DOI: 10.1002/jps.24574</identifier><identifier>PMID: 26296055</identifier><identifier>CODEN: JPMSAE</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Administration, Inhalation ; aerosols ; Algorithms ; amorphous ; Chemistry, Pharmaceutical - standards ; dry powder inhaler ; Dry Powder Inhalers - standards ; engineered particles ; excipients ; Humans ; inhalation ; Inhaled by design ; Particle Size ; powder technology ; Powders - standards ; protein delivery ; pulmonary delivery/adsorption</subject><ispartof>Journal of pharmaceutical sciences, 2015-10, Vol.104 (10), p.3259-3288</ispartof><rights>2015 Wiley Periodicals, Inc. and the American Pharmacists Association</rights><rights>2015 Wiley Periodicals, Inc. and the American Pharmacists Association.</rights><rights>Copyright © 2015 Wiley Periodicals, Inc., A Wiley Company</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4674-497dfa3060eec326f97f31980e2caa1bedd22b52ff35c23614e4a31f9a84c5983</citedby><cites>FETCH-LOGICAL-c4674-497dfa3060eec326f97f31980e2caa1bedd22b52ff35c23614e4a31f9a84c5983</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjps.24574$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjps.24574$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26296055$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Weers, Jeffry G.</creatorcontrib><creatorcontrib>Miller, Danforth P.</creatorcontrib><title>Formulation Design of Dry Powders for Inhalation</title><title>Journal of pharmaceutical sciences</title><addtitle>J Pharm Sci</addtitle><description>Drugs for inhalation are no longer exclusively highly crystalline small molecules. They may also be amorphous small molecules, peptides, antibodies, and myriad types of engineered proteins. The evolution of respiratory therapeutics has created a need for flexible formulation technologies to engineer respirable particles. These technologies have enabled medicinal chemists to focus on molecular design without concern regarding compatibility of physicochemical properties with traditional, blend-based technologies. Therapeutics with diverse physicochemical properties can now be formulated as stable and respirable dry powders. Particle engineering technologies have also driven the deployment of new excipients, giving formulators greater control over particle and powder properties. This plays a key role in enabling efficient delivery of drugs to the lungs. Engineered powder and device combinations enable aerosols that largely bypass the mouth and throat, minimizing the inherent variability among patients that arises from differences in oropharyngeal and airway anatomies and in breathing profiles. This review explores how advances among molecules, particles, and powders have transformed inhaled drug product development. Ultimately, this scientific progress will benefit patients, enabling new classes of therapeutics to be formulated as dry powder aerosols with improved efficacy, reduced variability and side effects, and improved patient adherence. © 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3259–3288, 2015</description><subject>Administration, Inhalation</subject><subject>aerosols</subject><subject>Algorithms</subject><subject>amorphous</subject><subject>Chemistry, Pharmaceutical - standards</subject><subject>dry powder inhaler</subject><subject>Dry Powder Inhalers - standards</subject><subject>engineered particles</subject><subject>excipients</subject><subject>Humans</subject><subject>inhalation</subject><subject>Inhaled by design</subject><subject>Particle Size</subject><subject>powder technology</subject><subject>Powders - standards</subject><subject>protein delivery</subject><subject>pulmonary delivery/adsorption</subject><issn>0022-3549</issn><issn>1520-6017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10MtKAzEUBuAgitbLwheQATe6GJvrXJZSrRcEC-o6pJkTTZmZ1KSj9O1NndaF6CqBfPnP4UfomOALgjEdzubhgnKR8y00IILiNMMk30aD-EZTJni5h_ZDmGGMMyzELtqjGS1X1wHCY-ebrlYL69rkCoJ9bRNnkiu_TCbuswIfEuN8cte-qR4doh2j6gBH6_MAvYyvn0e36cPjzd3o8iHVPMt5ysu8MorFgQCa0cyUuWGkLDBQrRSZQlVROhXUGCY0ZRnhwBUjplQF16Is2AE663Pn3r13EBaysUFDXasWXBckyQkuC0FzGunpLzpznW_jdt8K8ziWRHXeK-1dCB6MnHvbKL-UBMtVjTLWKL9rjPZkndhNG6h-5Ka3CIY9-LQ1LP9PkveTp00k639ALO3DgpdBW2g1VNaDXsjK2T8W-QLEaotX</recordid><startdate>201510</startdate><enddate>201510</enddate><creator>Weers, Jeffry G.</creator><creator>Miller, Danforth P.</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7QP</scope><scope>7QR</scope><scope>7TK</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>201510</creationdate><title>Formulation Design of Dry Powders for Inhalation</title><author>Weers, Jeffry G. ; Miller, Danforth P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4674-497dfa3060eec326f97f31980e2caa1bedd22b52ff35c23614e4a31f9a84c5983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Administration, Inhalation</topic><topic>aerosols</topic><topic>Algorithms</topic><topic>amorphous</topic><topic>Chemistry, Pharmaceutical - standards</topic><topic>dry powder inhaler</topic><topic>Dry Powder Inhalers - standards</topic><topic>engineered particles</topic><topic>excipients</topic><topic>Humans</topic><topic>inhalation</topic><topic>Inhaled by design</topic><topic>Particle Size</topic><topic>powder technology</topic><topic>Powders - standards</topic><topic>protein delivery</topic><topic>pulmonary delivery/adsorption</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Weers, Jeffry G.</creatorcontrib><creatorcontrib>Miller, Danforth P.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmaceutical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Weers, Jeffry G.</au><au>Miller, Danforth P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Formulation Design of Dry Powders for Inhalation</atitle><jtitle>Journal of pharmaceutical sciences</jtitle><addtitle>J Pharm Sci</addtitle><date>2015-10</date><risdate>2015</risdate><volume>104</volume><issue>10</issue><spage>3259</spage><epage>3288</epage><pages>3259-3288</pages><issn>0022-3549</issn><eissn>1520-6017</eissn><coden>JPMSAE</coden><abstract>Drugs for inhalation are no longer exclusively highly crystalline small molecules. They may also be amorphous small molecules, peptides, antibodies, and myriad types of engineered proteins. The evolution of respiratory therapeutics has created a need for flexible formulation technologies to engineer respirable particles. These technologies have enabled medicinal chemists to focus on molecular design without concern regarding compatibility of physicochemical properties with traditional, blend-based technologies. Therapeutics with diverse physicochemical properties can now be formulated as stable and respirable dry powders. Particle engineering technologies have also driven the deployment of new excipients, giving formulators greater control over particle and powder properties. This plays a key role in enabling efficient delivery of drugs to the lungs. Engineered powder and device combinations enable aerosols that largely bypass the mouth and throat, minimizing the inherent variability among patients that arises from differences in oropharyngeal and airway anatomies and in breathing profiles. This review explores how advances among molecules, particles, and powders have transformed inhaled drug product development. Ultimately, this scientific progress will benefit patients, enabling new classes of therapeutics to be formulated as dry powder aerosols with improved efficacy, reduced variability and side effects, and improved patient adherence. © 2015 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 104:3259–3288, 2015</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>26296055</pmid><doi>10.1002/jps.24574</doi><tpages>30</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-3549
ispartof Journal of pharmaceutical sciences, 2015-10, Vol.104 (10), p.3259-3288
issn 0022-3549
1520-6017
language eng
recordid cdi_proquest_miscellaneous_1710985272
source MEDLINE; Wiley Online Library Journals Frontfile Complete; Alma/SFX Local Collection
subjects Administration, Inhalation
aerosols
Algorithms
amorphous
Chemistry, Pharmaceutical - standards
dry powder inhaler
Dry Powder Inhalers - standards
engineered particles
excipients
Humans
inhalation
Inhaled by design
Particle Size
powder technology
Powders - standards
protein delivery
pulmonary delivery/adsorption
title Formulation Design of Dry Powders for Inhalation
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T04%3A48%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Formulation%20Design%20of%20Dry%20Powders%20for%20Inhalation&rft.jtitle=Journal%20of%20pharmaceutical%20sciences&rft.au=Weers,%20Jeffry%20G.&rft.date=2015-10&rft.volume=104&rft.issue=10&rft.spage=3259&rft.epage=3288&rft.pages=3259-3288&rft.issn=0022-3549&rft.eissn=1520-6017&rft.coden=JPMSAE&rft_id=info:doi/10.1002/jps.24574&rft_dat=%3Cproquest_cross%3E1710985272%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1710049801&rft_id=info:pmid/26296055&rft_els_id=S0022354916301137&rfr_iscdi=true